Biotech | May 02, 2022
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical
Avacc 3 has significant advantages over existing whooping cough vaccines
Avacc 3 has significant advantages over existing whooping cough vaccines
He will be leading the business, operations, P&L, and growth strategy for StanPlus
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Subscribe To Our Newsletter & Stay Updated
